BioSpace News Archive

Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, announced today that Capricor’s CEO, Linda Marbán, Ph.D, will participate on the panel “ Cell therapy for ARDS - When Remdesivir is not enough " hosted by Maxim Group and M-Vest on Wednesday, May 27 beginning at 10:00 a.m. Eastern time (7:00 a

Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, today announced that it received the CE mark for the WRAPSODY™ Endovascular Stent Graft System from the British Standards Institution (BSI).

Todos gains distribution rights to LifeCan Ventilator in Brazil, Mexico & Latin America Ventilator access will help prospective government and NGO procurers of COVID-related medical products reduce need for additional suppliers to address critical health needs L1 distribution network will provide untapped market access for Todos’ tests REHOVOT, Israel, SINGAPORE and NEW YORK, NY, May 26, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF) , an in vi

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced that it has priced a public offering of 4,000,000 American Depositary Shares (“ADSs”) (or ADS equivalents), each representing six hundred (600) of the Company’s ordinary shares, at an effective purchase price of $2.00 per ADS (or ADS equivalent). The closing of the offering is expected to

Expression Therapeutics has announced that it has received clearance by the United States Food and Drug Administration (FDA) to proceed following review of its Investigational New Drug Application (IND) for clinical testing of its novel lentiviral vector-based gene therapy — ET3 — for hemophilia A. Hemophilia A is the most common severe congen

Researchers Hope Giving Remdesivir Along with a Powerful Anti-Inflammatory Could be the Key to Treating the Most Severe COVID-19 Cases

Human growth hormone may prevent the loss of muscle strength after anterior cruciate ligament reconstruction, according to results from a pilot study conducted by investigators at Hospital for Special Surgery in collaboration with colleagues at the University of Michigan.

Factor Bioscience Inc., a Cambridge-based biotechnology company focused on developing therapeutic cell-engineering technologies, today announced that the United States Patent and Trademark Office has granted Factor Bioscience U.S. Patent No. 10,662,410 covering methods for producing a gene-edited cell using mRNA encoding transcription activator-like effector nucleases (TALENs)

Progenity, a biotechnology company with an established track record of success in developing and commercializing molecular testing products, announced the appointment of Damon Silvestry as Chief Operating Officer.

LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, announced today that William “BJ” Jones, Chief Commercial Officer, Migraine and Common Disease at Biohaven Pharmaceuticals, has joined LUNGevity’s Board of Directors.